Level C· Early human research exploring benefitsRetrospective StudyPubMedOpen access

Preliminary Report on the Time-Related Effect of a Single Autologous Adipose-Derived Mesenchymal Stem Cells Injection in Hip Osteoarthritis: A Retrospective Observational Study.

Braile A., De Cicco A., Liguori S., De Matteo V., Conza G., Vasso M.

Retrospective Study with a reported sample of 30 on Osteoarthritis, Hip Osteoarthritis, published in Adv Orthop (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Adv Orthop (2025)
Country
United States
Reported sample size
30
Source database
PubMed
PMID
40552343
PMCID
PMC12185193
DOI
10.1155/aort/3424035

Abstract (original English)

Background: Recently, intra-articular injection of mesenchymal stem cells (MSCs) had been proposed as a conservative treatment for hip osteoarthritis (HOA). Adipose tissue was demonstrated as a viable source of MSCs because of the high concentration of cells and the easy access to the donor site. The purpose of this study was to evaluate the time-related results of a single intra-articular injection of autologous adipose-derived stem cells (aASCs) in a series of patients with HOA. Methods: A retrospective study was conducted on 30 patients with HOA, who underwent an intra-articular injection of aASCs between September 2018 and January 2021. Inclusion criteria for the procedure were as follows: onset of symptoms of the affected hip in the prior six or more months ago, failure of the conservative treatment (NSAIDs and/or physiotherapy) and age > 18 years. Exclusion criteria were trauma in the affected hip occurred in the previous 3 months, recent arthroscopic treatment, infectious joint disease, chondromatosis of the hip or any other secondary HOA, malignancy, hyaluronic acid or other injections in the previous 6 months and incomplete follow-up. Because a low BMI makes extremely difficult to harvest enough adipose tissue, patients with a BMI < 18 were also excluded. The Oxford Hip Score, the 12-item Short Form Survey and Visual Analogue Scale were used to evaluate the results of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research